Preludedx and Quanterix Corporation Demonstrate Aidabreast Multi-Omic Assay for Early-Stage Invasive Breast Cancer

Published: 2026-04-17 13:50:35 ET QTRX

Published on 04/17/2026 at 01:50 pm EDT

PreludeDx and Quanterix Corporation highlighted that AidaBREAST?, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager HT platform using Opal? chemistry. This marks a significant milestone in the clinical translation of spatial proteomics.

The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer patients across four academic and clinical centers in the United States and Sweden, with a median follow-up of ~10 years. The study demonstrated the test to be both prognostic for 10-year locoregional recurrence risk and predictive for radiation therapy benefit, two capabilities not previously available to clinicians in a single assay for early-stage invasive breast cancer. AidaBREAST leverages the PhenoImager HT platform and Opal chemistry to obtain spatial multiplex protein expression, which is then integrated with targeted next-generation RNA sequencing for comprehensive assessment of tumor biology.

AidaBREAST? is the only risk assessment test for patients with stage I,IIa breast cancer that predicts radiation therapy benefit. The next-generation multi-omic assay developed by PreludeDx uses advanced spatial biology technology combining multiplex protein expression with targeted next-generation RNA sequencing to provide a comprehensive assessment of a patient?s tumor biology.

Leveraging the power of artificial intelligence, the assay integrates these complex data to generate a patient?s individualized risk assessment for 10-year locoregional recurrence and predict their benefit from radiation therapy. This innovative approach enables physicians to move beyond traditional measures offering patients personalized results with new insights into recurrence risk and radiation therapy benefit. This new information helps patients and their physicians to make more informed treatment decisions.